Bristol-Myers Squibb: Abilify Convention Booth, 2007|
BMS won a marketing and merchandising award for this lovely presentation.
Between 2004 and 2006 the FDA MedWatch program received 3,979 Individual Safety Reports naming Abilify (aripiprazole)
the Primary Suspect Drug for 1,182 distinct adverse reactions ranging from ageusia (loss of the sense of taste) to xanthopsia
(visual defect in which everything appears yellow).